SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Cardiovascular (CV) outcome trials (CVOTs) for sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1RAs) are crucial for managing type 2 diabetes (T2D).
• Direct comparative CVOTs between SGLT2is and GLP1RAs are lacking, necessitating indirect comparisons through network meta-analyses.
• Previous network meta-analyses relied on indirect evidence, yielding specific conclusions regarding CV outcomes.

Purpose of the Study:

• To conduct a meta-analysis of direct comparative CV outcome cohort studies of SGLT2is versus GLP1RAs.
• To evaluate the comparative effectiveness of SGLT2is and GLP1RAs in reducing major adverse cardiovascular events and mortality in T2D patients.
• To provide updated evidence for clinical decision-making regarding the choice between SGLT2is and GLP1RAs for CV risk reduction in T2D.

Main Methods:

• Meta-analysis of observational studies directly comparing SGLT2is and GLP1RAs.
• Inclusion of studies reporting cardiovascular death, all-cause mortality (ACM), and hospitalization for heart failure (HHF).
• Statistical analysis to assess the association between SGLT2is versus GLP1RAs and key CV outcomes.

Main Results:

• SGLT2is were associated with significantly lower risks of HHF compared to GLP1RAs.
• SGLT2is demonstrated significant reductions in CV death and ACM compared to GLP1RAs.
• The findings from direct comparative studies contrast with some indirect evidence from network meta-analyses.

Conclusions:

• SGLT2is may offer superior protection against HHF, CV death, and ACM compared to GLP1RAs in patients with T2D.
• These findings suggest a potential preference for SGLT2is over GLP1RAs for comprehensive CV risk management in T2D.
• Further research, including head-to-head randomized controlled trials, is warranted to confirm these findings.